Lily Cheung
CIK: 0001962207
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
PLIANT THERAPEUTICS, INC.
Discretionary Trading P&L
Holdings
Transaction History (10 total)
- Apr 17, 2026PLRX
PLIANT THERAPEUTICS, INC.
Award(A)DirectStock Option (Right to Buy)
52K shares- - Apr 17, 2026PLRX
PLIANT THERAPEUTICS, INC.
Award(A)DirectStock Option (Right to Buy)
51.8K shares- - Apr 17, 2026PLRX
PLIANT THERAPEUTICS, INC.
Disposition(D)DirectStock Option (Right to Buy)
51.8K shares- - Apr 17, 2026PLRX
PLIANT THERAPEUTICS, INC.
Disposition(D)DirectStock Option (Right to Buy)
123K shares- - Apr 17, 2026PLRX
PLIANT THERAPEUTICS, INC.
Award(A)DirectStock Option (Right to Buy)
123K shares- - Apr 17, 2026PLRX
PLIANT THERAPEUTICS, INC.
Disposition(D)DirectStock Option (Right to Buy)
52K shares- - Jan 22, 2026PLRX
PLIANT THERAPEUTICS, INC.
Award(A)DirectStock Option (Right to Buy)
300K shares- - Jan 20, 2026PLRX
PLIANT THERAPEUTICS, INC.
Sale(S)Direct7.5K shares at avg. $1.28$10K - Jan 23, 2025PLRX
PLIANT THERAPEUTICS, INC.
Award(A)Direct25.9K shares- - Jan 17, 2025PLRX
PLIANT THERAPEUTICS, INC.
Sale(S)Direct3.7K shares at avg. $11.20$42K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Apr 17, 2026 | PLRX PLIANT THERAPEUTICS, INC. | Award(A) Stock Option (Right to Buy) | 52,000 | - | - | Direct |
| Apr 17, 2026 | PLRX PLIANT THERAPEUTICS, INC. | Award(A) Stock Option (Right to Buy) | 51,750 | - | - | Direct |
| Apr 17, 2026 | PLRX PLIANT THERAPEUTICS, INC. | Disposition(D) Stock Option (Right to Buy) | 51,750 | - | - | Direct |
| Apr 17, 2026 | PLRX PLIANT THERAPEUTICS, INC. | Disposition(D) Stock Option (Right to Buy) | 123,000 | - | - | Direct |
| Apr 17, 2026 | PLRX PLIANT THERAPEUTICS, INC. | Award(A) Stock Option (Right to Buy) | 123,000 | - | - | Direct |
| Apr 17, 2026 | PLRX PLIANT THERAPEUTICS, INC. | Disposition(D) Stock Option (Right to Buy) | 52,000 | - | - | Direct |
| Jan 22, 2026 | PLRX PLIANT THERAPEUTICS, INC. | Award(A) Stock Option (Right to Buy) | 300,000 | - | - | Direct |
| Jan 20, 2026 | PLRX PLIANT THERAPEUTICS, INC. | Sale(S) | 7,534 | $1.28 | $9,644 | Direct |
| Jan 23, 2025 | PLRX PLIANT THERAPEUTICS, INC. | Award(A) | 25,875 | - | $0 | Direct |
| Jan 17, 2025 | PLRX PLIANT THERAPEUTICS, INC. | Sale(S) | 3,740 | $11.20 | $41,892 | Direct |
1-10 of 10 transactions
About Cheung Lily
Cheung Lily (SEC CIK 0001962207) files insider reports with the SEC as Chief Human Resource Officer of PLIANT THERAPEUTICS, INC. (PLRX).
Signal8 holds 5 ownership filings by Cheung Lily, all Form 4s, filed between Jan 22, 2025 and Apr 17, 2026. Those filings report 10 transactions, from Jan 17, 2025 to Apr 17, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Cheung Lily's filings is in SOUTH SAN FRANCISCO, CA.
Recent filings by Cheung Lily
- Apr 17, 2026: Grants or awards of PLRX derivative securities (2 lines, Form 4, code A).
- Apr 17, 2026: Disposition to issuer transactions of PLRX derivative securities (2 lines, Form 4, code D).
- Apr 17, 2026: Grant or award of PLRX derivative securities (Form 4, code A).
- Apr 17, 2026: Disposition to issuer transaction of PLRX derivative securities (Form 4, code D).
- Jan 22, 2026: Grant or award of PLRX derivative securities (Form 4, code A).
Other insiders filing for PLIANT THERAPEUTICS, INC. (PLRX)
- Raben David, Chief Medical Officer
- Iannone Robert, Director
- Borellini Flavia, Director
- CROWELL GAYLE A, Director
- MCCOURT Thomas A, Director
- Krognes Steve E., Director